Vipoglanstat

Phase 2Small molecule

GGesynta Pharma AB

Vipoglanstat is one of 41 small molecule programs targeting Endometriosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

EndometriosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Phase 3

16 2

Lupron

AbbVie

Phase 3

1 3

Revia

Teva

Phase 3

1 4

Leuprorelin

Takeda

Phase 3

8 5

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 6

Trental

VValidus Pharmaceuticals

Phase 3

1 7

Firmagon

Ferring

Phase 3

1 8

Estradiol/norethindrone Acetate

AbbVie

Phase 3

5 9

EE20/DRSP(BAY86-5300)

Bayer

Phase 3

1 10

Indole-3-Carbinol

UUniversity of Kansas Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Endometriosis

NCT07260669

Clinical

Trials by Indication[1]

Endometriosis1 trial

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Recruiting·GGesynta Pharma AB·Phase 2·NCT07260669·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vipoglanstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vipoglanstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vipoglanstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gesynta Pharma AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGesynta Pharma AB

Vipoglanstat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News